SENORES
Senores Pharmaceuticals Ltd.
Each stock's 10,000-path forecast, rendered as light.
Senores Pharmaceuticals Ltd. (SENORES) Stock Analysis & Case Study
Is SENORES a good buy? The data-driven verdict.
Senores Pharmaceuticals Ltd. (SENORES) trades at ₹1,328,on the numbers it tread carefully, a Downstox Snapshot Score of 36/100.
On the numbers, Senores Pharmaceuticals Ltd. (SENORES) tread carefully, a Downstox Snapshot Score of 36/100, weighing expensive at 48.4× earnings, ROE of 13.4%, a 51% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
SENORES fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How SENORES ranks against the 2,373 companies in our screener
- SENORES's market cap of 6,183 Cr ranks in the 69th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SENORES's book value of ₹203 ranks in the 72nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SENORES's promoter holding of 45.8% ranks in the 24th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SENORES's 3-year profit (PAT) growth of 139.0% ranks in the top 3% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SENORES's 3-year revenue growth of 162.0% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SENORES's debt-to-equity ratio of 0.37x is lower than 45% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is SENORES overvalued? SENORES P/E vs peers
SENORES trades at 48.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
SENORES share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 1.6y of SENORES history (55%/yr drift, 47%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| SENORES 2027 | ₹749 | ₹1,353 | ₹2,444 | +1% |
| SENORES 2028 | ₹581 | ₹1,364 | ₹3,203 | +2% |
| SENORES 2029 | ₹473 | ₹1,375 | ₹3,998 | +2% |
| SENORES 2030 | ₹412 | ₹1,386 | ₹4,656 | +3% |
| SENORES 2031 | ₹364 | ₹1,397 | ₹5,359 | +4% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability SENORES goes up, or doubles?
The bull case for SENORES
- SENORES's return on equity of 13.4% ranks in the 65th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹3,998.
The bear case & risks
- SENORES's P/E of 48.9x is lower than 27% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- High historical volatility (47%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹473.
SENORES volatility & expected range, how bumpy is the ride?
Over the last 1.6 years SENORES compounded at 55%/year with annualized volatility of 47%. That volatility implies a 1-year 80% range of ₹749-₹2,444, the honest backbone behind any single price target.
SENORES price forecast, the full 60-month probability fan
SENORES price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds SENORES hits common targets within the simulated horizon?
Full multi-horizon detail on the SENORES price target & forecast page.
SENORES Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. SENORES scores 5/8, mixed financial health.
SENORES MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy SENORES with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 34.51% | 2.9× |
| Groww | 34.63% | 2.9× |
| Dhan | 34.51% | 2.9× |
| Kotak NeoCHEAPEST | 34.48% | 2.9× |
| Paytm Money | 35.22% | 2.8× |
| Pocketful | 34.68% | 2.9× |
| FyersCHEAPEST | 34.48% | 2.9× |
| Anand Rathi | 34.51% | 2.9× |
| Bajaj Broking | 42.00% | 2.4× |
| Share India | 34.63% | 2.9× |
Compare every broker on the SENORES MTF page.
About Senores Pharmaceuticals Ltd.: sector, index & market-cap context
Senores Pharmaceuticals Ltd. (SENORES) is a small-cap NSE-listed company, with a market capitalisation of ₹6,121 Cr. See more stocks on our screener.
How the SENORES Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Senores Pharmaceuticals Ltd.'s public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
SENORES analysis, FAQs
Is Senores Pharmaceuticals Ltd. (SENORES) a good buy?
On the numbers, Senores Pharmaceuticals Ltd. (SENORES) tread carefully, a Downstox Snapshot Score of 36/100, weighing expensive at 48.4× earnings, ROE of 13.4%, a 51% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is SENORES overvalued or undervalued?
SENORES trades at 48.4× earnings, expensive versus the ~22× long-run Nifty average.
What is the SENORES share price target for 2031?
SENORES's probability-weighted 2031 median target is ₹1,397, with an 80% range of ₹364-₹5,359 (10,000-path Monte-Carlo).
What is the probability SENORES doubles in 5 years?
The modelled probability of SENORES reaching ₹2,685 (2×) within 5 years is 26%.
What is the bull case for SENORES?
SENORES's return on equity of 13.4% ranks in the 65th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in SENORES?
SENORES's P/E of 48.9x is lower than 27% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. High historical volatility (47%/yr) means a wide, bumpy range of outcomes, size positions accordingly.